GPIbα CAAR-T

GPIbα CAAR-T is an experimental chimeric autoantibody receptor (CAAR) T-cell therapy designed for the treatment of immune thrombocytopenia (ITP). The therapy utilizes T cells engineered to express the native ectodomain of platelet glycoprotein Ib alpha (GPIbα) as the extracellular binding domain of a second-generation chimeric receptor. This design allows the CAAR-T cells to specifically recognize and eliminate autoreactive B cells that express anti-GPIbα B-cell receptors (BCRs) on their surface. By selectively depleting the specific B-cell clones responsible for producing pathogenic autoantibodies against platelets, GPIbα CAAR-T aims to restore platelet counts while preserving healthy B-cell populations, potentially overcoming the limitations of broad B-cell depletion therapies like rituximab. Preclinical studies have demonstrated selective cytolysis of anti-GPIbα B cells and reduction of autoantibody titers in xenograft models.

Other names

GPIbα-based CAAR-T cellsGPIbα CAAR-T cells